INHA

Summary

INHA (inhibin subunit alpha, HGNC:6065) is a protein-coding gene on chromosome 2q35, encoding Inhibin alpha chain (P05111). Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland.

This gene encodes a member of the TGF-beta (transforming growth factor-beta) superfamily of proteins. The encoded preproprotein is proteolytically processed to generate multiple peptide products, including the alpha subunit of the inhibin A and B protein complexes. These complexes negatively regulate follicle stimulating hormone secretion from the pituitary gland. Inhibins have also been implicated in regulating numerous cellular processes including cell proliferation, apoptosis, immune response and hormone secretion. Mutations in this gene may be associated with male infertility and premature ovarian failure in female human patients.

Source: NCBI Gene 3623 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 60 total
• GTEx eGene: eQTL in 25 tissues, sQTL in 0 (q < 0.05)
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.42 (intermediate), LOEUF 0.69 (unconstrained)
• MANE Select transcript: NM_002191
• Notable: 60 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6065
Approved symbol	INHA
Name	inhibin subunit alpha
Location	2q35
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000123999
Ensembl biotype	protein_coding
OMIM	147380
Entrez	3623

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000243786

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1

ENST00000243786, ENST00000489456, ENST00001100373, ENST00001140573

RefSeq mRNA: 1 — MANE Select: NM_002191 NM_002191

CCDS: CCDS2444

Canonical transcript exons

ENST00000243786 — 2 exons

Exon	Start	End
ENSE00000843609	219572310	219572642
ENSE00000843610	219574694	219575711

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 97.42.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.8256 / max 208.2761, expressed in 156 samples.

Highest expression (Bgee): adrenal tissue, testis, adrenal gland, ovary, adrenal gland cortex.

Genetic regulation across tissues (GTEx eQTL / sQTL)

INHA is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 25 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 25 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Thyroid	eqtl	1.9e-40	-0.37	2:219575996:A:C
Nerve Tibial	eqtl	1.3e-11	+0.19	2:219572251:A:G
Esophagus Muscularis	eqtl	5.0e-08	+0.18	2:219572251:A:G
Cells Cultured fibroblasts	eqtl	5.1e-08	+0.15	2:219572251:A:G
Brain Caudate basal ganglia	eqtl	5.7e-06	+0.18	2:219572251:A:G
Muscle Skeletal	eqtl	2.4e-05	+0.18	2:219572251:A:G
Brain Cortex	eqtl	4.7e-05	+0.22	2:219572251:A:G
Skin Not Sun Exposed Suprapubic	eqtl	1.3e-04	+0.15	2:219572251:A:G
Brain Anterior cingulate cortex BA24	eqtl	3.3e-04	+0.22	2:219572251:A:G
Artery Tibial	eqtl	7.0e-04	+0.15	2:219572251:A:G
Whole Blood	eqtl	3.2e-03	+0.27	2:220032689:C:A
Heart Left Ventricle	eqtl	3.2e-03	-0.20	2:219567987:A:T
Artery Coronary	eqtl	3.3e-03	+1.15	2:219965758:C:A
Adipose Subcutaneous	eqtl	3.8e-03	+0.13	2:219572251:A:G
Brain Putamen basal ganglia	eqtl	4.6e-03	-0.35	2:219587877:G:A
Brain Substantia nigra	eqtl	5.4e-03	+0.24	2:220493506:G:A
Liver	eqtl	9.6e-03	+0.33	2:219861526:T:C
Brain Hypothalamus	eqtl	1.1e-02	+0.18	2:219572251:A:G
Pancreas	eqtl	1.4e-02	+0.17	2:219572251:A:G
Brain Amygdala	eqtl	1.5e-02	-0.23	2:219567987:A:T

FANTOM5 promoters

6 alternative TSS:

Promoter ID	TPM avg	Samples expressed
25528	0.3448	67
25529	0.1602	70
25525	0.1432	27
25527	0.1288	27
25526	0.0374	14
202578	0.0112	2

Top tissues by expression

showing 100 of 288 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	97.42	gold quality
right testis	UBERON:0004534	96.72	gold quality
left testis	UBERON:0004533	96.66	gold quality
right adrenal gland	UBERON:0001233	95.45	gold quality
testis	UBERON:0000473	95.22	gold quality
left ovary	UBERON:0002119	94.36	gold quality
right adrenal gland cortex	UBERON:0035827	94.16	gold quality
left adrenal gland	UBERON:0001234	93.65	gold quality
right ovary	UBERON:0002118	92.78	gold quality
left adrenal gland cortex	UBERON:0035825	92.44	gold quality
adrenal gland	UBERON:0002369	92.42	gold quality
adrenal cortex	UBERON:0001235	91.58	gold quality
ovary	UBERON:0000992	87.90	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.57	gold quality
right atrium auricular region	UBERON:0006631	80.80	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.52	gold quality
adult organism	UBERON:0007023	79.75	gold quality
cardiac atrium	UBERON:0002081	78.51	gold quality
placenta	UBERON:0001987	75.96	gold quality
nucleus accumbens	UBERON:0001882	75.91	gold quality
decidua	UBERON:0002450	75.84	silver quality
body of pancreas	UBERON:0001150	75.63	gold quality
right hemisphere of cerebellum	UBERON:0014890	75.50	gold quality
cerebellar hemisphere	UBERON:0002245	75.41	gold quality
cerebellar cortex	UBERON:0002129	75.20	gold quality
right frontal lobe	UBERON:0002810	73.93	gold quality
adenohypophysis	UBERON:0002196	73.78	gold quality
caudate nucleus	UBERON:0001873	73.08	gold quality
putamen	UBERON:0001874	73.01	gold quality
pituitary gland	UBERON:0000007	72.68	gold quality
metanephros cortex	UBERON:0010533	72.67	gold quality
cerebellum	UBERON:0002037	72.66	gold quality
stromal cell of endometrium	CL:0002255	71.68	gold quality
right lobe of thyroid gland	UBERON:0001119	71.10	gold quality
left lobe of thyroid gland	UBERON:0001120	70.71	gold quality
cingulate cortex	UBERON:0003027	70.53	gold quality
heart	UBERON:0000948	70.32	gold quality
anterior cingulate cortex	UBERON:0009835	70.31	gold quality
left uterine tube	UBERON:0001303	70.11	gold quality
heart left ventricle	UBERON:0002084	69.26	gold quality
thyroid gland	UBERON:0002046	69.25	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.16	gold quality
amygdala	UBERON:0001876	69.06	gold quality
cardiac ventricle	UBERON:0002082	68.78	gold quality
body of uterus	UBERON:0009853	68.69	gold quality
mucosa of stomach	UBERON:0001199	68.66	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	68.24	gold quality
apex of heart	UBERON:0002098	67.79	gold quality
hypothalamus	UBERON:0001898	67.29	gold quality
endocervix	UBERON:0000458	66.77	gold quality
right uterine tube	UBERON:0001302	66.64	gold quality
ectocervix	UBERON:0012249	66.57	gold quality
pancreas	UBERON:0001264	66.12	gold quality
skin of leg	UBERON:0001511	65.88	gold quality
female reproductive system	UBERON:0000474	65.58	gold quality
forebrain	UBERON:0001890	65.53	gold quality
brain	UBERON:0000955	65.43	gold quality
prefrontal cortex	UBERON:0000451	65.42	gold quality
lower esophagus muscularis layer	UBERON:0035833	65.35	gold quality
lower esophagus	UBERON:0013473	65.32	gold quality
neocortex	UBERON:0001950	65.30	gold quality
central nervous system	UBERON:0001017	65.19	gold quality
skin of abdomen	UBERON:0001416	65.06	gold quality
cortical plate	UBERON:0005343	65.06	gold quality
telencephalon	UBERON:0001893	65.00	gold quality
tibial nerve	UBERON:0001323	64.91	gold quality
frontal cortex	UBERON:0001870	64.63	gold quality
pancreatic ductal cell	CL:0002079	64.52	silver quality
right lung	UBERON:0002167	64.00	gold quality
paraflocculus	UBERON:0005351	63.86	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	63.73	gold quality
frontal pole	UBERON:0002795	63.57	gold quality
left coronary artery	UBERON:0001626	63.21	gold quality
cerebral cortex	UBERON:0000956	63.16	gold quality
middle frontal gyrus	UBERON:0002702	63.08	gold quality
omental fat pad	UBERON:0010414	62.64	gold quality
peritoneum	UBERON:0002358	62.58	gold quality
ascending aorta	UBERON:0001496	62.56	gold quality
thoracic aorta	UBERON:0001515	62.51	gold quality
metanephros	UBERON:0000081	62.47	gold quality
zone of skin	UBERON:0000014	62.29	gold quality
endometrium epithelium	UBERON:0004811	62.21	gold quality
lower esophagus mucosa	UBERON:0035834	62.13	gold quality
descending thoracic aorta	UBERON:0002345	62.06	gold quality
right coronary artery	UBERON:0001625	61.96	gold quality
minor salivary gland	UBERON:0001830	61.93	gold quality
coronary artery	UBERON:0001621	61.86	gold quality
heart right ventricle	UBERON:0002080	61.80	gold quality
adipose tissue of abdominal region	UBERON:0007808	61.48	gold quality
prostate gland	UBERON:0002367	61.43	gold quality
esophagus	UBERON:0001043	61.07	gold quality
aorta	UBERON:0000947	60.95	gold quality
body of stomach	UBERON:0001161	60.69	gold quality
muscle layer of sigmoid colon	UBERON:0035805	60.43	gold quality
anatomical system	UBERON:0000467	60.39	gold quality
gastrocnemius	UBERON:0001388	60.34	gold quality
Ammon’s horn	UBERON:0001954	60.08	gold quality
multicellular organism	UBERON:0000468	60.06	gold quality
material anatomical entity	UBERON:0000465	60.05	gold quality
tibial artery	UBERON:0007610	60.04	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-124263	yes	1564.29
E-GEOD-134144	yes	628.53
E-ANND-3	no	0.96

HPA expression

RNA tissue specificity: Group enriched

showing 60 of 69 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Testis	tissue	55.8	high
Adrenal gland	tissue	40.0	high
Ovary	tissue	34.3	medium
Pancreas	tissue	11.6	not detected
Placenta	tissue	10.6	low
Frontal cortex	tissue	9.4
Pituitary gland	tissue	7.1
Caudate putamen	tissue	5.5
Nucleus accumbens	tissue	4.9
Postcentral gyrus	tissue	4.7
Heart muscle	tissue	4.6	not detected
Hippocampus	tissue	3.6	not detected
Cerebral cortex	tissue	2.5	not detected
Somatosensory cortex	tissue	2.5
Hypothalamus	tissue	2.3
Locus coeruleus	tissue	2.3
Periaqueductal gray	tissue	2.3
Thalamus	tissue	2.1
Skin 1	tissue	2.0	not detected
Epididymis	tissue	2.0	not detected
Amygdala	tissue	2.0
Cerebellum	tissue	2.0	not detected
Basal ganglia	tissue	1.9	not detected
Choroid plexus	tissue	1.9
Midbrain	tissue	1.9
Superior colliculi	tissue	1.9
Hippocampal formation	tissue	1.9
Retrosplenial and cingulate cortex	tissue	1.9
Temporal cortex	tissue	1.9
Occipital cortex	tissue	1.9
Insular cortex	tissue	1.9
Pons	tissue	1.8
Motor cortex	tissue	1.8
Entorhinal cortex	tissue	1.8
Ventral forebrain	tissue	1.8
Septum	tissue	1.8
Prefrontal cortex	tissue	1.7
Retina	tissue	1.7
Retrosplenial cortex	tissue	1.7
Vagina	tissue	1.5	not detected
Salivary gland	tissue	1.5	not detected
Medulla oblongata	tissue	1.5
Substantia nigra	tissue	1.3
Olfactory bulb	tissue	1.3
Putamen	tissue	1.2
Spinal cord	tissue	1.2
Seminal vesicle	tissue	1.1	not detected
Fallopian tube	tissue	1.0	not detected
Thyroid gland	tissue	0.9	not detected
Prostate	tissue	0.8	not detected
Parathyroid gland	tissue	0.7	not detected
Endometrium 1	tissue	0.7	not detected
Breast	tissue	0.5	not detected
Smooth muscle	tissue	0.4	not detected
Gallbladder	tissue	0.4	not detected
Corpus callosum	tissue	0.4
Kidney	tissue	0.3	not detected
Cervix	tissue	0.2	not detected
Stomach 1	tissue	0.2	not detected
Adipose tissue	tissue	0.2	not detected

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Precentral gyrus (6.1), Olfactory area (4.6), Ventral periolivary nuclei (4.6), Motor facial nucleus (4.5), Central amygdala (4.4).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB1, CTNNB1, DNMT3A, GATA1, GATA4, GATA6, LEF1, NR4A1, NR5A1, NR5A2, SMAD2, SMAD3, TCF7L2, TFAP2A, WT1

miRNA regulators (miRDB)

Targeting INHA by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

19 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-449C-5P	99.78	67.63	1168
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-5089-5P	98.45	66.06	1388
HSA-MIR-1910-3P	98.44	67.51	1695
HSA-MIR-224-5P	98.33	70.12	1256
HSA-MIR-6511A-5P	98.13	67.47	1770
HSA-MIR-22-5P	97.67	68.92	1355

Functional genomics

gnomAD constraint: pLI 0.423, LOEUF 0.686, missense Z 0.753 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000243786 — one region, missense o/e 0.94.

Literature-anchored findings (GeneRIF, showing 40)

• DNA hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma (PMID:11818495)
• Patients affected by premature ovarian failure for the missense mutation (769G–>A transition) in the exon 2 of the INHalpha gene. (PMID:12093833)
• findings suggest that inhibin A is a specific marker of early pregnancy loss before the onset of the clinical symptoms of recurrent miscarriage (PMID:12456605)
• To determine which cell types in the testes may produce inhibin B, the localization of the two subunits of inhibin B was examined in adult testicular biopsies with normal spermatogenesis, spermatogenic arrest, or Sertoli cell only tubules. (PMID:12493718)
• Preliminary results show that inhibin A levels are raised in Asian women affected with fetal Down syndrome and sex chromosome abnormality. (PMID:12576745)
• data suggest that the increased placental expression of inhibin subunit mRNAs is part of the mechanism leading to increased serum activin A and inhibin A levels (PMID:12587530)
• Results quantify the relative expression of inhibin alpha, inhibin/activin beta(A), beta(B), beta(C), follistatin, activin receptors and beta-glycan genes in placental tissue of term pre-eclamptic patients. (PMID:12651901)
• results suggest dissociation between major sources of inhibin A and inhibin pro-alpha C in early pregnancy; identified a link between production of pro-alpha C and luteal steroidogenesis and a predominantly feto-placental origin of inhibin A (PMID:12660265)
• estradiol exerts a greater role over inhibin in FSH-negative feedback regulation during the luteal phase while inhibin A and/or B plays a more critical role as the follicular phase progresses (PMID:12679471)
• Mast cell-derived activin A may play an important role in airway remodeling in patients with asthma at least in part by mediating the proliferation of airway smooth muscle cells. (PMID:12682233)
• Proportions of precursor inhibin B and alpha-subunit forms in the circulation are unchanged in men with spermatogenic disorders indicating there is no alteration of the Sertoli cell inhibin secretory pattern. (PMID:12721183)
• significant correlation between arterial and venous levels of inhibin A, inhibin B and activin A was found in umbilical cord artery and vein; findings suggest the placenta is the main source of inhibin B and the fetus of activin A in the umbilical cord (PMID:12857425)
• Molecular analysis of the katG codon 315 and the promoter region of the inhA is a good alternative to diagnose isoniazid resistance in South Kore.a (PMID:14596968)
• role as a marker for pregnancy viability (PMID:14667886)
• Serum inhibin A may be helpful in predicting the failure of pregnancies. (PMID:14967395)
• The INHalpha gene is a strong candidate gene for ovarian failure (PMID:15205401)
• study expands the immunophenotype of granular cell tumor (S100, CD68, protein gene product 9.5, and inhibin-alpha) regardless of location and supports a neural origin (PMID:15214825)
• no variation between the normal subjects and the premature ovarian failure patients; G769A variation of INHalpha is rare in Korea women with POF. (PMID:15227735)
• Activin A and inhibin A appear to be viable candidates as laboratory parameters for detection of pregnancy induced hypertension. (PMID:15236099)
• Women with premature ovarian failure showed low levels of inhibin A (PMID:15374731)
• review article supports the hypothesis that tumor suppressor activities of the inhibin alpha subunit dominate in non-malignant tissue, but its oncogenic activities emerge during tumorigenesis (PMID:15451570)
• Expressed in Sertoli cells in oligozoospermia. (PMID:15551748)
• Ovulatory cycles were characterized by higher FSH and lower inhibin A leveels in hypergonadotropic hypogonadism or premature ovarian failure. (PMID:15562017)
• Inhibin A expressed in primary clear cell renal cell carcinoma (2/16, 13%) and metastatic clear cell renal cell carcinoma (3/5, 60%). (PMID:15578072)
• The lower inhibin alpha and betaglycan expression in endometrial adenocarcinoma suggests that the inhibin action may be disrupted. (PMID:15745937)
• Inhibin A and activin A may be used as markers to predict pregnancies that are likely to miscarry. (PMID:15950648)
• conclude that obese women present less percentage variation of both inhibin A and B during the menstrual cycle, associated with a low frequency of ovulatory cycles (PMID:16048795)
• Discordant pattern of inhibin A and inhibin B during the rat estrous cycle is due to independent populations of antral follicles making inhibin B (small antral follicles) or inhibin A (large antral follicles). (PMID:16195413)
• Inheritance of specific INHA promoter haplotypes predispose to the development of premature ovarian failure. (PMID:16390856)
• 16C>T and 769G>A variants in INHalpha gene may not be associated to premature ovarian failure disease. (PMID:16396934)
• A strong colocalisation of inhibin-alpha and -betaA could be demonstrated in malignant endometrial tissue. (PMID:16423381)
• analysis of inhibin and transforming growth factor beta-binding sites on betaglycan (PMID:16621788)
• Higher levels of inhibin A and B are associated with oocyte presence but not with fertilization rates. (PMID:16650414)
• A significant lower expression of the inhibin-alpha subunit in IUGR extravillous trophoblast compared to normal pregnancies was observed. (PMID:16670820)
• polymorphisms in the INHA gene may have a role in ovarian failure (PMID:16723387)
• dimeric inhibins do not play a central role in the endocrinological imbalance observed in polycystic ovary syndrome (PMID:16758344)
• inhibin A may have a role in development of severe preeclampsia (PMID:16778388)
• The present findings showed that treatment with vaginal estroprogestinic decreases serum inhibin A and inhibin B levels, the follicular diameter. (PMID:16989826)
• The lower expression of follistatin and beta A subunit in women with recurrent miscarriage may imply an altered activity of activin A at the time of decidualization, which may lead to poor pregnancy outcome in the form of miscarriage. (PMID:17074342)
• glycosylation of Asn(302) of the alpha-subunit of inhibin A and B results in a decrease in bioactivity, and the effect on inhibin A, at least, is explained by its reduced affinity to betaglycan (PMID:17272393)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	inha	ENSDARG00000052433
mus_musculus	Inha	ENSMUSG00000032968
rattus_norvegicus	Inha	ENSRNOG00000020097

Paralogs (31): TGFB2 (ENSG00000092969), BMP7 (ENSG00000101144), TGFB1 (ENSG00000105329), BMP5 (ENSG00000112175), BMP8B (ENSG00000116985), TGFB3 (ENSG00000119699), INHBA (ENSG00000122641), BMP4 (ENSG00000125378), BMP2 (ENSG00000125845), GDF5 (ENSG00000125965), GDF1 (ENSG00000130283), BMP15 (ENSG00000130385), GDF15 (ENSG00000130513), GDF11 (ENSG00000135414), MSTN (ENSG00000138379), INHBE (ENSG00000139269), LEFTY2 (ENSG00000143768), GDF7 (ENSG00000143869), BMP3 (ENSG00000152785), BMP6 (ENSG00000153162), GDF6 (ENSG00000156466), NODAL (ENSG00000156574), INHBB (ENSG00000163083), BMP10 (ENSG00000163217), GDF9 (ENSG00000164404), INHBC (ENSG00000175189), BMP8A (ENSG00000183682), GDF3 (ENSG00000184344), LEFTY1 (ENSG00000243709), GDF2 (ENSG00000263761), GDF10 (ENSG00000266524)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:96569) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 36 distinct phenotype terms.

Mouse phenotype (MP)	Records
increased ovary tumor incidence	3
increased adrenal gland tumor incidence	2
increased ovary weight	2
cachexia	2
increased testis tumor incidence	2
kyphoscoliosis	1
abnormal liver morphology	1
abnormal oocyte morphology	1
abnormal ovarian follicle morphology	1
enlarged testis	1
abnormal spermatogenesis	1
decreased body weight	1
anemia	1
extended life span	1
increased circulating follicle stimulating hormone level	1
reduced female fertility	1
male infertility	1
female infertility	1
increased litter size	1
premature death	1
decreased circulating follicle stimulating hormone level	1
maternal effect	1
ovary hemorrhage	1
increased testis weight	1
increased uterus weight	1

+11 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bos taurus	P07994	97.4%	Diamond
Ovis aries	P38440	97.4%	Diamond
Sus scrofa	P04087	89.4%	Diamond
Equus caballus	P55101	88.6%	Diamond
Trichosurus vulpecula	O77755	74.5%	Diamond
Gallus gallus	P43031	53.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ASIC4-AS1	ncRNA	105373885
TMEM198	protein-coding	130612
OBSL1	protein-coding	23363
ASIC4	protein-coding	55515
CHPF	protein-coding	79586
MIR3132	ncRNA	100423039
STK11IP	protein-coding	114790
SLC4A3	protein-coding	6508
GMPPA	protein-coding	29926

Protein

Protein identifiers

Inhibin alpha chain — P05111 (reviewed: P05111)

All UniProt accessions (1): P05111

UniProt curated annotations — full annotation on UniProt →

Function. Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins. Inhibin A is a dimer of alpha/INHA and beta-A/INHBA that functions as a feedback regulator in the hypothalamic-pituitary-gonadal (HPG) axis. Inhibits the secretion of FSH from the anterior pituitary gland by acting on pituitary gonadotrope cells. Antagonizes activin A by binding to the proteoglycan, betaglycan, and forming a stable complex with and, thereby, sequestering type II activin receptors while excluding type I receptor. Inhibin B is a dimer of alpha and beta-B that plays a crucial role in the regulation of the reproductive system by inhibiting the secretion of follicle-stimulating hormone (FSH) from the anterior pituitary gland. Thereby, maintains reproductive homeostasis in both males and females. Acts as a more potent suppressor of FSH release than inhibin A. Functions as competitive receptor antagonist binding activin type II receptors with high affinity in the presence of the TGF-beta type III coreceptor/TGFBR3L.

Subunit / interactions. Dimeric, linked by one or more disulfide bonds. Activin B is a dimer of alpha and beta-B. Inhibin A is a dimer of alpha and beta-A. Inhibin B is a dimer of alpha and beta-B. Interacts with TGFBR3L; this interaction regulates female fertility.

Subcellular location. Secreted.

Tissue specificity. Originally found in ovary (granulosa cells) and testis (Sertoli cells), but widely distributed in many tissues including brain and placenta. In adrenal cortex expression is limited to the zona reticularis and the innermost zona fasciculata in the normal gland, extending centripetally into the zona fasciculata in hyperplasia. Also found in adrenocortical tumors. Also expressed in prostate epithelium of benign prostatic hyperplasia, in regions of basal cell hyperplasia and in nonmalignant regions of high grade prostate cancer. Only circulating inhibin B is found in male, whereas circulating inhibins A and B are found in female.

Post-translational modifications. Proteolytic processing yields a number of bioactive forms. The 20/23 kDa forms consist solely of the mature alpha chain, the 26/29 kDa forms consist of the most N-terminal propeptide linked through a disulfide bond to the mature alpha chain, the 50/53 kDa forms encompass the entire proprotein. Each type can be furthermore either mono- or diglycosylated, causing the mass difference.

Similarity. Belongs to the TGF-beta family.

RefSeq proteins (1): NP_002182* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001839	TGF-b_C	Domain
IPR015615	TGF-beta-like	Family
IPR017175	Inhibin_asu	Family
IPR017948	TGFb_CS	Conserved_site
IPR029034	Cystine-knot_cytokine	Homologous_superfamily

Pfam: PF00019

UniProt features (23 total): mutagenesis site 5, disulfide bond 4, sequence variant 3, glycosylation site 3, propeptide 2, sequence conflict 2, site 2, signal peptide 1, chain 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P05111-F1	70.80	0.26

Human Protein Atlas

Protein class: Predicted secreted proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles; golgi apparatus

Antibody reliability (HPA): IH enhanced · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2)

Position	Role
61–62	cleavage
232–233	cleavage

Disulfide bonds (4)

Type	Positions
Disulfide bond	291–363, 295–365, 262–328
Interchain	327

Glycosylation sites (3)

Type	Positions
N-linked (glcnac…) asparagine	146, 268, 302

Mutagenesis-validated functional residues (5)

Position	Phenotype
56–57	loss of cleavage; when associated with 60-aa-61.
60–61	loss of cleavage; when associated with 55-aa-56.
231–232	loss of cleavage.
268	loss of glycosylation.
302	loss of glycosylation.

Function

Pathways and Gene Ontology

Reactome pathways

3 curated (TAS) of 10; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

10 pathways:

ID	Pathway	Evidence
R-HSA-209822	Glycoprotein hormones	curated
R-HSA-201451	Signaling by BMP	curated
R-HSA-9839406	TGFBR3 regulates activin signaling	curated
R-HSA-392499	Metabolism of proteins	—
R-HSA-209952	Peptide hormone biosynthesis	—
R-HSA-2980736	Peptide hormone metabolism	—
R-HSA-162582	Signal Transduction	—
R-HSA-1502540	Signaling by Activin	electronic
R-HSA-9006936	Signaling by TGFB family members	—
R-HSA-9839373	Signaling by TGFBR3	—

MSigDB gene sets: 249 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_HEMOGLOBIN_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, MYOGENIN_Q6, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_B_CELL_ACTIVATION, GCANCTGNY_MYOD_Q6, GOBP_ERYTHROCYTE_HOMEOSTASIS, GOBP_NEGATIVE_REGULATION_OF_B_CELL_ACTIVATION, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT

GO Biological Process (23): skeletal system development (GO:0001501), ovarian follicle development (GO:0001541), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), cell surface receptor protein serine/threonine kinase signaling pathway (GO:0007178), cell-cell signaling (GO:0007267), male gonad development (GO:0008584), cell differentiation (GO:0030154), erythrocyte differentiation (GO:0030218), negative regulation of type II interferon production (GO:0032689), negative regulation of activin receptor signaling pathway (GO:0032926), regulation of cell population proliferation (GO:0042127), negative regulation of phosphorylation (GO:0042326), hemoglobin biosynthetic process (GO:0042541), negative regulation of B cell differentiation (GO:0045578), negative regulation of macrophage differentiation (GO:0045650), negative regulation of cell cycle (GO:0045786), positive regulation of follicle-stimulating hormone secretion (GO:0046881), negative regulation of follicle-stimulating hormone secretion (GO:0046882), regulation of cell cycle (GO:0051726), regulation of follicle-stimulating hormone secretion (GO:0046880), system development (GO:0048731), negative regulation of multicellular organismal process (GO:0051241)

GO Molecular Function (8): signaling receptor binding (GO:0005102), cytokine activity (GO:0005125), hormone activity (GO:0005179), growth factor activity (GO:0008083), inhibin binding (GO:0034711), protein-containing complex binding (GO:0044877), protein binding (GO:0005515), protein sequestering activity (GO:0140311)

GO Cellular Component (8): photoreceptor outer segment (GO:0001750), photoreceptor inner segment (GO:0001917), extracellular region (GO:0005576), plasma membrane (GO:0005886), inhibin-betaglycan-ActRII complex (GO:0034673), neuronal cell body (GO:0043025), inhibin A complex (GO:0043512), inhibin B complex (GO:0043513)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Signaling by TGFB family members	3
Peptide hormone biosynthesis	1
Signaling by TGFBR3	1
Peptide hormone metabolism	1
Metabolism of proteins	1
Signal Transduction	1

GO top-level categories

53 GO namespaces:

Category	Terms
regulation of cellular process	3
protein binding	3
receptor ligand activity	3
cellular anatomical structure	3
animal gross anatomical part developmental process	2
cell communication	2
signaling	2
cell cycle	2
regulation of follicle-stimulating hormone secretion	2
follicle-stimulating hormone secretion	2
binding	2
inhibin complex	2
system development	1
female gonad development	1
cellular process	1
cellular response to stimulus	1
signal transduction	1
enzyme-linked receptor protein signaling pathway	1
gonad development	1
development of primary male sexual characteristics	1
cellular developmental process	1
myeloid cell differentiation	1
erythrocyte homeostasis	1
negative regulation of cytokine production	1
type II interferon production	1
regulation of type II interferon production	1
activin receptor signaling pathway	1
regulation of activin receptor signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
cell population proliferation	1
phosphorylation	1
regulation of phosphorylation	1
negative regulation of phosphate metabolic process	1
macromolecule biosynthetic process	1
hemoglobin metabolic process	1
B cell differentiation	1
regulation of B cell differentiation	1
negative regulation of lymphocyte differentiation	1
negative regulation of B cell activation	1
negative regulation of myeloid leukocyte differentiation	1
macrophage differentiation	1
regulation of macrophage differentiation	1
negative regulation of cellular process	1
regulation of cell cycle	1
positive regulation of gonadotropin secretion	1
negative regulation of gonadotropin secretion	1
molecular sequestering activity	1
photoreceptor cell cilium	1
membrane	1
cell periphery	1
plasma membrane protein complex	1
somatodendritic compartment	1
cell body	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 40 annotations. The rest are phylogenetic / computational / electronic (IEA).

8 experimentally-supported GO terms:

GO term	NS	Evidence
hemoglobin biosynthetic process	BP	direct assay
negative regulation of activin receptor signaling pathway	BP	direct assay
regulation of cell cycle	BP	direct assay
regulation of cell population proliferation	BP	direct assay
inhibin A complex	CC	direct assay
inhibin-betaglycan-ActRII complex	CC	direct assay
plasma membrane	CC	direct assay
signaling receptor binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 782 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
INHA	ALPI	P09923	758
INHA	ALPP	P05187	684
INHA	SIX5	Q8N196	631
INHA	BMP15	O95972	628
INHA	FSHR	P23945	628
INHA	GDF9	O60383	600
INHA	AMH	P03971	586
INHA	INHBA	P08476	579
INHA	INHBB	P09529	577
INHA	GLIS3	Q8NEA6	572
INHA	FIGLA	Q6QHK4	542
INHA	LHCGR	P22888	541
INHA	IGFBP5	P24593	509
INHA	CHRND	Q07001	508
INHA	INSL3	P51460	491

IntAct

Human interaction partners of INHA in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
SIAH1	physical association	0.560	6
HSPA5	association	0.530	2
PPP2R3B	physical association	0.400	1
MOCS3	association	0.350	1
TCF4	association	0.350	1
TMEM129	association	0.350	1

BioGRID (18 interactions; top human partners by supporting records): CALR (Affinity Capture-MS; 3 records), HSPA5 (Affinity Capture-MS; 3 records), IKBKG (Affinity Capture-MS; 3 records), PDIA3 (Affinity Capture-MS; 3 records), SIAH1 (Two-hybrid; 2 records), ACVR2A (Affinity Capture-Western), DVL2 (Affinity Capture-MS), FAHD1 (Affinity Capture-MS), PPP2R3B (Affinity Capture-MS)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
INHA	down-regulates	TGFBR3	binding

Ligand–receptor pairs (CellPhoneDB) (12)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

12 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
ACVR1B;ACVR2A		Signaling by Inhibin/Activin
ACVR1;ACVR2B		Signaling by Inhibin/Activin
ACVR1B;ACVR2B		Signaling by Inhibin/Activin
ACVR1;ACVR2A		Signaling by Inhibin/Activin
ACVR1C;ACVR2A		Signaling by Inhibin/Activin
ACVR1C;ACVR2B		Signaling by Inhibin/Activin
ACVR1C;ACVR2B	ligand	Signaling by Inhibin/Activin
ACVR1;ACVR2A	ligand	Signaling by Inhibin/Activin
ACVR1B;ACVR2A	ligand	Signaling by Inhibin/Activin
ACVR1;ACVR2B	ligand	Signaling by Inhibin/Activin
ACVR1C;ACVR2A	ligand	Signaling by Inhibin/Activin
ACVR1B;ACVR2B	ligand	Signaling by Inhibin/Activin

Disease & clinical

Genetic variants

Variant evidence for INHA: 60 ClinVar records (0 pathogenic / likely pathogenic).

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	9
Benign	3

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 19 predictions of 82):

Position(s)	Effect	Δscore	Sites
2:219574692–219574693	acceptor_loss	0.9900	5
2:219574693	acceptor_loss	0.9800
2:219574689	acceptor_gain	0.9700
2:219572643–219572644	donor_loss	0.9600	6
2:219572642	donor_loss	0.9300
2:219572642	donor_loss	0.9200
2:219574682	acceptor_gain	0.9200
2:219573052	acceptor_gain	0.8800
2:219572642	donor_loss	0.8500
2:219572645	donor_loss	0.8100

AlphaMissense

403 missense substitutions predicted likely pathogenic (of 2,301 scored), across 116 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F271	8	0.971	0.995
F288	8	0.927	0.982
F214	8	0.921	0.987
F115	8	0.903	0.985
F86	8	0.882	0.966
F286	8	0.857	0.980
C291	7	0.984	0.991
C262	7	0.974	0.989
C328	7	0.970	0.984
C363	7	0.967	0.982
C365	7	0.960	0.977
W276	7	0.957	0.997
C295	7	0.946	0.972
W279	7	0.937	0.994
C327	7	0.895	0.935
F350	7	0.892	0.966
W176	7	0.891	0.987
W132	7	0.889	0.965
C200	7	0.883	0.952
D345	7	0.883	0.937

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Lung Adenocarcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	unfavorable	0.00015

Disease associations

OMIM: gene MIM:147380 | disease phenotypes:

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5169109 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 11,405 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL497318	CANNABIGEROL	2	11,405

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Cannabigerol	KI	2600 nM

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.28	IC50	5200	nM	CANNABIGEROL

PubChem BioAssay actives

1 with measured affinity, of 1 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol	1845667: Inhibition of Inh (unknown origin)	ic50	5.2000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, increases methylation	2
sodium arsenite	decreases expression	2
Benzo(a)pyrene	decreases methylation, increases mutagenesis	2
OTX015	decreases expression	1
mivebresib	decreases expression	1
glycidyl methacrylate	decreases expression	1
testosterone undecanoate	affects cotreatment, decreases expression	1
terbufos	increases methylation	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol S	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Troglitazone	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	increases reaction, increases expression	1
Cocaine	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dibutyl Phthalate	increases expression	1
Diethylhexyl Phthalate	increases expression	1
Doxorubicin	affects expression	1
Fonofos	increases methylation	1
Endosulfan	increases expression	1
Estradiol	decreases expression	1
Flame Retardants	decreases expression	1
Lead	affects expression	1
Parathion	increases methylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5096678	Binding	Inhibition of Inh (unknown origin)	Phytocannabinoid Pharmacology: Medicinal Properties of Cannabis sativa Constituents Aside from the “Big Two”. — *J Nat Prod*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 75 trials:

NCT	Phase	Status	Title
NCT00417066	Phase 4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	Phase 4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	Phase 4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	Phase 4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	Phase 4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	Phase 4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	Phase 3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	Phase 2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	Phase 2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	Phase 2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	Phase 2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	Phase 2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	Phase 2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	Phase 1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	Phase 1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	Phase 1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	Phase 1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	Phase 1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	Phase 2/3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	Phase 2/3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	Phase 1/2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	Phase 1/2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	Phase 1/2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	Phase 1/2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	Phase 1/2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	Phase 1/2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	Phase 1/2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	Phase 1/2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	Phase 1/2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	Phase 1/2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	Phase 1/2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	Phase 1/2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	Phase 1/2	COMPLETED	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	Early Phase 1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	Early Phase 1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	Early Phase 1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists
NCT00295087	Not specified	COMPLETED	X-Chromosome Inactivation Status and Premature Ovarian Failure
NCT00417157	Not specified	COMPLETED	Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH
NCT00619333	Not specified	UNKNOWN	Inactive FSH in Galactosemia
NCT00780897	Not specified	UNKNOWN	Premature Ovarian Failure (Genetic and Physiopathologic Analysis)
NCT01187524	Not specified	TERMINATED	The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry
NCT01411644	Not specified	UNKNOWN	Pheno- & Genotyping POF (WHO III)
NCT02086318	Not specified	UNKNOWN	A New Algorithm to Predict Ovarian Age
NCT02467231	Not specified	ACTIVE_NOT_RECRUITING	Ovarian Reserve After Cancer: Longitudinal Effects
NCT02696889	Not specified	COMPLETED	Rejuvenation of Premature Ovarian Failure With Stem Cells
NCT02779374	Not specified	TERMINATED	Autologous Bone Marrow Transplantation for Premature Ovarian Insufficiency
NCT03207412	Not specified	UNKNOWN	Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency
NCT03381300	Not specified	ACTIVE_NOT_RECRUITING	Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome
NCT03412487	Not specified	UNKNOWN	Ovarian Histopathology and Laparoscopic Assessment of Premature Ovarian Failure
NCT03474120	Not specified	UNKNOWN	Prospective Genetic Study in Patients With Ovarian Insufficiency
NCT03480412	Not specified	UNKNOWN	Second Step Protocol in Poor Ovarian Responder (POR)
NCT03840824	Not specified	COMPLETED	Blood Spot Self-administered Test and Assay
NCT03861715	Not specified	UNKNOWN	Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.
NCT03924648	Not specified	COMPLETED	Endocan Levels in Women With Premature Ovarian Insufficiency
NCT04149028	Not specified	COMPLETED	Platelet Rich Plasma Injection Into Ovary of Patients With Premature Ovarian Insufficiency
NCT04189406	Not specified	UNKNOWN	Turner Syndrome Minipuberty Study

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for INHA across ~30M SureChEMBL compounds — explore on Sugi Predict.